Skip to nav Skip to content

Clinical Trial Search

302 Clinical Trials Found

Clinical Trial 21415

Disease Site: Other Hematopoietic
PI: Kuykendall, Andrew

Clinical Trial 21626

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
Disease Site: Lung
PI: Gray, Jhanelle

Clinical Trial 21707

A Proof of Concept Study of TBio-4101 (an Autologous selected and expanded tumor infiltrating lymphocyte [TIL] therapy) Using Short-Term Cultured, Selected Autologous TIL following a Lymphodepleting Chemotherapy Regimen and Followed by IL-2 for Patients with Relapsed or Refractory Solid Tumors (Phase 1)
Disease Site: Colon, Melanoma, skin, Rectum
PI: Sarnaik, Amod

Clinical Trial 21887

A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes
Disease Site: Other
PI: Padron, Eric

Clinical Trial 21986

A Phase 2, Multicenter, Randomized, Open-Label Study of DS-7300a, a B7-H3 Antibody Drug Conjugate (ADC), in Subjects with Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Disease Site: Lung
PI: Chiappori, Alberto

Clinical Trial 22002

A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS
Disease Site: Any Site, Liver, Lung, Other Digestive Organ, Pancreas, Small Intestine, Stomach
PI: Kim, Dae Won

Clinical Trial 22003

A Phase II Randomized Study of Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer with PSA Progression while on NHA and LHRH Analog
Disease Site: Prostate
PI: Zhang, Jingsong

Clinical Trial 22071

Melanoma Margins Trial (MelMarT-II): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma
Disease Site: Other
PI: Zager, Jonathan

Clinical Trial 22095

Disease Site: Myeloid and Monocytic Leukemia
PI: Kuykendall, Andrew

Clinical Trial 22096

A Phase 1 Open-Label, Dose-Escalation, Safety, and Tolerability Study of JSP191 as a Second-line Therapy in Subjects with Lower-Risk Myelodysplastic Syndrome (LR-MDS)
Disease Site: Other Hematopoietic
PI: Lancet, Jeffrey

Clinical Trial 22100

Disease Site: Multiple Myeloma
PI: Grajales-Cruz, Ariel

Clinical Trial 22305

Disease Site: Breast, Lung, Other Respiratory and Intrathoracic Organs
PI: Soyano Muller, Aixa